Skip to main content

Advertisement

SpringerLink
Log in

Debate: Postmastectomy Radiation Therapy in T1/2N1 Disease

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Although postmastectomy radiation therapy is known to reduce local recurrence in patients with T1/2N1 breast cancer, some have postulated that not all patients require this treatment. In this era of genomic analyses and personalized therapy, clinicians have debated whether the toxicity of post-mastectomy radiation therapy (PMRT) can be avoided for some subsets of patients. However, the data in this regard remain controversial, particularly as surgeons de-escalate the surgical management of the axilla. Several ongoing clinical trials may provide a glimpse into optimal management in this scenario. However, the “right” answer to this debate currently remains unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–26.

    Article  Google Scholar 

  2. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247–53.

    Article  Google Scholar 

  3. Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol. 2016;34:4431–42.

    Article  Google Scholar 

  4. NCCN. NCCN Clinical practice guidelines in oncology (NCCN guidelines). Breast Cancer. 2021;4:2021.

  5. McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.

    Article  CAS  Google Scholar 

  6. McBride A, Allen P, Woodward W, et al. Locoregional recurrence risk for patients with T1,2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89:392–8.

    Article  Google Scholar 

  7. Leonardi MC, Scognamiglio IR, Maisonneuve P, et al. Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated. Breast Cancer Res Treat. 2021;188:511–24.

    Article  CAS  Google Scholar 

  8. Wang S, Wen G, Tang Y, et al. Effectiveness of the AJCC 8th-edition staging system for selecting patients with T1–2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions. BMC Cancer. 2020;20:792.

    Article  CAS  Google Scholar 

  9. Wang J, Tang Y, Jing H, et al. Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy. BMC Cancer. 2020;20:1132.

    Article  Google Scholar 

  10. Tang Y, Zhang YJ, Zhang N, et al. Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes. Cancer. 2020;126(Suppl 16):3857–66.

    Article  Google Scholar 

  11. Luo C, Zhong X, Deng L, Xie Y, Hu K, Zheng H. Nomogram predicting locoregional recurrence to assist decision-making of postmastectomy radiation therapy in patients with T1–2N1 breast cancer. Int J Radiat Oncol Biol Phys. 2019;103:905–12.

    Article  Google Scholar 

  12. Li M, Yue J, Wan X, et al. Risk-adapted postmastectomy radiotherapy decision based on prognostic nomogram for pT1-2N1M0 breast cancer: a multicenter study. Front Oncol. 2020;10:588859.

    Article  Google Scholar 

  13. Yin H, Qu Y, Wang X, et al. Impact of postmastectomy radiation therapy in T1–2 breast cancer patients with 1–3 positive axillary lymph nodes. Oncotarget. 2017;8:49564–73.

    Article  Google Scholar 

  14. Bhutiani N, Egger ME, Stromberg AJ, Bhutiani IK, Ajkay N, McMasters KM. Identifying factors impacting the efficacy of postmastectomy radiotherapy in patients with early-stage breast cancer and one to two positive lymph nodes. J Surg Oncol. 2020;122:128–33.

    Article  Google Scholar 

  15. Scheer AS, Zih FS, Maki E, Koch CA, McCready DR. Post-mastectomy radiation: should subtype factor into the decision? Ann Surg Oncol. 2016;23:2462–70.

    Article  Google Scholar 

  16. Tseng YD, Uno H, Hughes ME, et al. Biological subtype predicts risk of locoregional recurrence after mastectomy and impact of postmastectomy radiation in a large national database. Int J Radiat Oncol Biol Phys. 2015;93:622–30.

    Article  Google Scholar 

  17. Moo TA, McMillan R, Lee M, et al. Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1–T2 breast cancer and 1–3 positive lymph nodes. Ann Surg Oncol. 2014;21:1569–74.

    Article  Google Scholar 

  18. Goodman CR, Seagle BL, Kocherginsky M, Donnelly ED, Shahabi S, Strauss JB. 21-Gene recurrence score assay predicts benefit of post-mastectomy radiotherapy in T1–2 N1 breast cancer. Clin Cancer Res. 2018;24:3878–87.

    Article  CAS  Google Scholar 

  19. Zhang WW, Tong Q, Sun JY, et al. 21-Gene recurrence score assay could not predict benefit of post-mastectomy radiotherapy in T1–2 N1mic ER-positive HER2-negative breast cancer. Front Oncol. 2019;9:270.

    Article  Google Scholar 

  20. Mamounas EP, Liu Q, Paik S, et al. 21-Gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. 2017;109(4):djw259.

    Article  Google Scholar 

  21. Zeidman M, Schmidt H, Alberty-Oller JJ, et al. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB). Breast Cancer Res Treat. 2021;187:177–85.

    Article  CAS  Google Scholar 

  22. Riedel F, Hoffmann AS, Moderow M, et al. Time trends of neoadjuvant chemotherapy for early breast cancer. Int J Cancer. 2020;147:3049–58.

    Article  CAS  Google Scholar 

  23. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30:3960–6.

    Article  Google Scholar 

  24. Wang Q, Zhao J, Han X, et al. Is there a role for post-mastectomy radiotherapy for T1–2N1 breast cancers with node-positive pathology after patients become node-negative pathology following neoadjuvant chemotherapy? Front Oncol. 2020;10:892.

    Article  Google Scholar 

  25. Kim M, Kim SW, Lee SU, et al. A model to estimate the risk of breast cancer-related lymphedema: combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:498–503.

    Article  Google Scholar 

  26. Miller CL, Specht MC, Skolny MN, et al. Risk of lymphedema after mastectomy: potential benefit of applying ACOSOG Z0011 protocol to mastectomy patients. Breast Cancer Res Treat. 2014;144:71–7.

    Article  Google Scholar 

  27. Johnson AR, Kimball S, Epstein S, et al. Lymphedema incidence after axillary lymph node dissection: quantifying the impact of radiation and the lymphatic microsurgical preventive healing approach. Ann Plast Surg. 2019;82:S234–41.

    Article  CAS  Google Scholar 

  28. Naoum GE, Roberts S, Brunelle CL, et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: long-term results from a prospective screening trial. J Clin Oncol. 2020;38:3430–8.

    Article  Google Scholar 

  29. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75.

    Article  Google Scholar 

  30. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.

    Article  CAS  Google Scholar 

  31. Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385–93.

    Article  Google Scholar 

  32. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.

    Article  Google Scholar 

  33. Peintinger F, Reitsamer R, Stranzl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003;89:648–52.

    Article  CAS  Google Scholar 

  34. Kell MR, Burke JP, Barry M, Morrow M. Outcome of axillary staging in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010;120:441–7.

    Article  Google Scholar 

  35. Baker NF, Baecher KM, Hart AM, Styblo TM, Carlson GW, Losken A. The impact of axillary node surgery on outcomes following immediate breast reconstruction. Breast J. 2020;26:2170–6.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Yale University School of Medicine, New Haven, CT, USA

    Anees B. Chagpar MD, MSc, MPH, MA, MBA

Authors
  1. Anees B. Chagpar MD, MSc, MPH, MA, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anees B. Chagpar MD, MSc, MPH, MA, MBA.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chagpar, A.B. Debate: Postmastectomy Radiation Therapy in T1/2N1 Disease. Ann Surg Oncol 28, 5456–5460 (2021). https://doi.org/10.1245/s10434-021-10500-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10500-5

Search

Navigation